(thirdQuint)A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects.

 Objectives: Primary Objective: To compare the pharmacokinetic characteristics of two isosorbide -5 -mononitrate extended -release tablets 40 mg of Qilu Pharmaceutical Co.

, Ltd, China and ISMO Retard (isosorbide -5 -mononitrate extended -release tablet) 40 mg, distributed by RIEMSER Pharma GmbH.

 following a single oral dose administration in healthy Chinese subjects under fed condition.

 Secondary Objective: To monitor the safety profile of the subjects exposed to the Investigational Medicinal Product.

 Study Design: a randomized, open label, balanced, 3-way crossover, single dose study under fed conditions.

12 subjects will be randomized to one of the 3 treatment sequences.

 Each treatment sequence will consist of 3 periods, separated by a washout period of at least 7 days.

 For sequence 1, first reference drug, then test formulation 1 and test formulation 2 will be administered.

 The order for sequence 2 is test formulation 2, reference drug and test formulation 1.

 The order for sequence 3 is test formulation 1, test formulation 2 and reference drug.

.

 A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects@highlight

The purpose of this trial is to compare the pharmacokinetic characteristics of two isosorbide -5 -mononitrate extended -release tablets 40 mg of Qilu Pharmaceutical Co.

, Ltd and ISMO Retard (isosorbide -5 -mononitrate extended -release tablet) 40 mg, distributed by RIEMSER Pharma GmbH.

 Primary endpoints are Cmax, AUC(0-t) and AUC(0-inf).

 Secondary endpoints are Tmax, t1/2 and z.

